Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs
Tóm tắt
In the United States, access to buprenorphine remains low and disparities regarding who receives treatment have emerged. Federal laws have regulated buprenorphine delivery, ultimately limiting its implementation more broadly. At the onset of the COVID-19 pandemic, federal agencies acted quickly to remove a legal barrier, effectively allowing people with opioid used disorder (OUD) to initiate buprenorphine treatment via telemedicine. Leveraging this policy shift, a low barrier buprenorphine treatment initiative via telemedicine was started at syringe service programs in California. We assessed early findings from participants reached by this model of treatment. In May 2020, buprenorphine treatment was offered through a virtual platform to SSP participants in California. SSP staff connected interested participants to virtual appointments with medical providers in a private location. During these visits, clinicians conducted clinical assessments for diagnosing participants with OUD and developed an unsupervised home induction plan for individuals who were eligible. Participants were prescribed a 7-day supply of up to 16 mg daily buprenorphine or 16 mg buprenorphine-2 mg naloxone and asked to return the following week if interested in continuing treatment. From May 2020 to March 2021, the SSP-buprenorphine virtual care initiative inducted 115 participants onto treatment with 87% of participants inducted on the same day as their referral. Of those inducted, 58% were between the ages of 30 and 49 and 28% were cisgender female. Regarding participants’ method of payment to reimburse buprenorphine costs, 92% of participants were covered by Medicare/Medicaid. Overall, 64% of participants returned for a second buprenorphine prescription refill. These early findings suggest that this could be a promising approach to improve equity and access to buprenorphine treatment. We encourage policymakers to continue allowing buprenorphine delivery via telemedicine and researchers to study whether this approach improves equity and access to treatment throughout the United States.
Tài liệu tham khảo
Substance Abuse and Mental Health Services Administration. Trends in the use of methadone, buprenorphine and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). 2015. https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport-3192.html.
US Department of Health and Human Services. Geographic disparities affect access to buprenorphine services for opioid use disorder. 2020. https://oig.hhsg.ov/oei/reports/oei-12-17-00240.asp . Accessed 19 Nov 2020.
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–42.
Olfson M, Zhang VS, Schoenbaum M, King M. Trends in buprenorphine treatment in the United States, 2009–2018. JAMA. 2020;323(3):276–7.
Davis CS, Samuels EA. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy. 2021;93:102905. https://doi.org/10.1016/j.drugpo.2020.102905.
Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–81.
Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, et al. Overdose education and naloxone distribution within syringe service programs - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117–21.
Lambdin B, Bluthenthal R, Tookes HE, Wenger L, Lakosky P, Kral A. Understanding the impact of COVID-19 on the penetration of naloxone distribution from syringe service programs in the United States. In: Dissemination and implementation research conference (oral abstract; virtual due to COVID). 2021.
Javed Z, Burk K, Facente S, Pegram L, Ali A, Asher A. Syringe services programs: a technical package of effective strategies and approaches for planning, designing and implementation. 2020. https://www.cdc.gov/ssp/docs/SSP-Technical-Package.pdf. Accessed 29 Nov 2021.
Heinzerling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, et al. Unmet need for recommended preventive health services among clients of California syringe exchange programs: implications for quality improvement. Drug Alcohol Depend. 2006;81(2):167–78.
Martinez A, Bluthenthal R, Flynn NM, Andersen R, Kral A. HIV risks and seroprevalence among Mexican American injection drug users in California. AIDS Behav. 2011;15(1):95–102.
CDC. Use of syringe services programs increases, but access must improve for greater HIV prevention: promising signs in HIV prevention among African Americans and Latinos. 2016. https://www.cdc.gov/media/releases/2016/p1129-HIV-syringe-services.html. Accessed 6 Dec 2021.
Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20.
Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, et al. Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124:108283.
Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136–8.
Harris R, Rosecrans A, Zoltick M, Willman C, Saxton R, Cotterell M, Bell J, Blackwell I, Page KR. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. Drug Alcohol Depend. 2022;230:109187. https://doi.org/10.1016/j.drugalcdep.2021.109187.
Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356–64.
Bachhuber MA, Thompson C, Prybylowski A, Benitez JM, Mazzella SM, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;39(2):167–72.
Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;176:133–8.
Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abuse Treat. 2019;101:38–49.
Zheng W, Nickasch M, Lander L, Wen S, Xiao M, Marshalek P, et al. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis. J Addict Med. 2017;11(2):138–44.
Figgatt MC, Salazar ZR, Vincent L, Carden-Glenn D, Link K, Kestner L, et al. Treatment experiences for skin and soft tissue infections among participants of syringe service programs in North Carolina. Harm Reduct J. 2021;18(1):80.